Table 1.
Demographics
| Healthy Subjects | Patients With Psychosis | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| NP Normal | NP Impaired | ||||||||
| Sample Size | 97 | 41 | 90 | ||||||
| Variable | Mean | SD | Mean | SD | Mean | SD | F/t/x 2 | P | Post Hoc a |
| Age | 33.3 | 11.5 | 28.9 | 10.3 | 34.6 | 12.9 | 3.32 | .038 | NP I>NP N |
| Education | 5.2 | 1.5 | 4.4 | 1.6 | 3.5 | 1.2 | 34.59 | <.001 | HS>NP N, NP I |
| Sex (M/F) | 52/45 | 29/12 | 50/40 | 3.68 | .159 | ||||
| Race (C/AA/O) | 62/29/6 | 32/7/2 | 55/29/6 | 3.82 | .431 | ||||
| Diagnosis (BP/SCZ) | — | — | 13/28 | 17/73 | 2.62 | .105 | |||
| Premorbid IQ | 106.7 | 8.8 | 105.9 | 7.0 | 96.2 | 10.9 | 32.02 | <.001 | HS, NP N>NP I |
| Current NP functioning | −0.06 | 0.84 | −0.17 | 0.68 | −2.08 | 0.92 | 149.56 | <.001 | HS, NP N>NP I |
| Age at illness onset | — | — | 21.9 | 4.7 | 22.1 | 8.3 | 0.20 | .840 | — |
| Duration of illness | — | — | 7.0 | 8.8 | 12.3 | 12.0 | 2.53 | .012 | — |
| PANSS positive | — | — | 16.9 | 8.1 | 19.9 | 6.4 | 2.30 | .023 | — |
| PANSS negative | — | — | 12.3 | 5.7 | 14.7 | 7.0 | 1.87 | .064 | — |
| PANSS general | — | — | 28.3 | 7.3 | 32.4 | 7.8 | 4.10 | .005 | — |
| APD dose (CPZ equiv) | — | — | 319.4 | 143.9 | 502.3 | 285.3 | 3.64 | <.001 | — |
Note: AA = African American; APD = antipsychotic drug; BP = bipolar disorder; C = Caucasian; CPZ = chlorpromazine; F = female; HS = healthy subjects; NP = neuropsychologically; I = impaired; N = normal; M = male; O = other; PANSS=Positive and Negative Syndrome Scale; SCIP = Screen for Cognitive Impairment in Psychiatry; SCZ = schizophrenia. Education coded as follows: 1 = Grade 6 or less; 2 = Grade 7–12; 3 = high school; 4 = part college; 5 = graduated 2-year college; 6 = graduated 4-year college; 7 = part graduate/professional school; 8 = completed graduate/professional school.
aBonferroni corrected for multiple comparisons.